AlphAIAlphAI — Financial news for AI agents
yahoo.comSEP 221 min read$BAX

Is Baxter Stock Underperforming the Nasdaq?

Baxter International (BAX) has underperformed rival Becton, Dickinson (BDX) with a 22.8% gain over 52 weeks but lagged on a YTD basis with an 18.3% increase. Analysts give BAX a consensus 'Hold' rating, with a mean price target of $27, implying an 18.4% upside from current levels.

Original reporting
yahoo.com
Published Sep 22, 2026, 10:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 11:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Is Baxter Stock Underperforming the Nasdaq? — source image
Source · yahoo.com
Decision brief

The 30-second read

$BAXNeutralLow
01

Why it matters

Analyst consensus Hold and a $27 price target suggest limited upside, likely keeping the stock range‑bound.

02

Market read

The article provides a modest analyst price‑target update for Baxter, offering limited trading impetus.

03

What to watch

Potential upcoming earnings or product news could change the valuation beyond the current target.

Relevance 5/10Novelty 5/10Timing: current

Background

Baxter International (BAX) is a U.S. medical‑device and pharmaceutical company; Becton Dickinson (BDX) is a competitor referenced for performance comparison.

Company-level read

Ticker impact

$BAXNeutralMedium confidence
Context

Analysts maintain a Hold rating on Baxter with a mean price target of $27, implying 18.4% upside.

Expected impact

Potential modest upside if market reprices toward the $27 target.

Evidence & confidence

A consensus Hold and a modest upside estimate are typical analyst updates that may influence short‑term positioning but lack a strong catalyst.

Market effects

Sector

The update reflects broader health‑care sector sentiment but does not signal a sector shift.

Regional

Limited impact confined to U.S. health‑care equities.

Global

Minimal global relevance beyond Baxter's shareholder base.

Counterpoint

What could challenge this read

Some traders may view the modest upside as insufficient and could short Baxter if broader market rallies.

Key entities

  • Company
    Baxter International

    Subject of the analyst rating update.

  • Company
    Becton Dickinson

    Peer mentioned for performance comparison only.

Read at source← All news

Related articles

SEP 2
$BAXLow

What Baxter International (BAX)'s CFO Transition Means For Shareholders

Baxter International (BAX) appointed John Rogers as CFO, with CEO Andrew Hider temporarily assuming CFO duties. Rogers brings cross-industry experience, potentially influencing capital allocation and reporting. Baxter aims for $12.4B revenue and $788.3M earnings by 2029, requiring 2.8% yearly revenue growth. The company recently launched a $600M tender offer for longer-dated notes, amending its credit agreement. Investors focus on margin stabilization and leverage.

simplywall.st3 min
AUG 21
$BAXLow

Baxter hires CFO from Smith & Nephew

Baxter named John Rogers as its new CFO, effective October 1. Rogers previously served as CFO of Smith & Nephew. Baxter's CEO, Andrew Hider, stated Rogers will aid in stabilizing the business and driving continuous improvement. Rogers' appointment follows Baxter's multiyear restructuring, including the sale of its biopharma and kidney care businesses. Baxter reiterated its 2026 financial outlook.

yahoo.com1 min
AUG 17
$BAXMed

Baxter’s interim CFO is leaving for Cardinal Health

Baxter said in SEC filings that interim CFO Anita Zielinski will leave in September. She will join Cardinal Health as chief accounting officer and SVP of finance on Nov. 5, with a $750,000 sign-on bonus and $1 million in time-vesting RSUs. Baxter has not named a successor. Baxter recently raised its full-year outlook to 3%-4% sales growth and adjusted EPS of $1.95-$2.15.

massdevice.com4 min
AUG 8
$BAXMedAI 8/10

Why Baxter International Stock Skyrocketed by 19% This Week

Baxter International shares rose about 19% this week after the company reported a Q2 earnings beat and raised full-year guidance, according to S&P Global Market Intelligence and Baxter. Q2 sales were $2.96B, up 5% year over year, and GAAP net income rose to $135M. Baxter now expects 2025 sales growth of 3% to 4% and adjusted EPS of $1.95 to $2.15.

aol.com4 min
AUG 1
$BAXMedAI 8/10

Why Baxter International Stock Skyrocketed by 19% This Week

Baxter International shares rose about 19% over the week after the company reported encouraging Q2 results. Baxter posted $2.96B revenue, up 5% year over year, and GAAP net income of $135M. Adjusted EPS was $0.56. Analysts expected $2.8B revenue and $0.37 adjusted EPS. Baxter raised FY guidance to 3%-4% sales growth and adjusted EPS of $1.95-$2.15.

fool.com3 min
JUL 31
$MSFTHighAI 8/10

Stocks Rally on Stellar Microsoft Earnings and Chip Stock Strength

US stocks rose as investors digested strong Q2 earnings expectations and results, led by Microsoft. The article cites Bloomberg Intelligence forecasts for Q2 earnings up about 23% and notes 86% of 243 S&P 500 firms beat estimates. It also reports chip and AI-infrastructure gains tied to Lam Research and other semis, while some software names fell.

yahoo.com7 min